Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Yilan Xu; Panruo Jiang; Zhenyan Xu; Haige Ye

doi:10.3389/fimmu.2024.1348852

Frontiers in Immunology (Feb 2024)

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Yilan Xu,
Panruo Jiang,
Zhenyan Xu,
Haige Ye

Affiliations

Yilan Xu: Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Panruo Jiang: Department of Hematology, Dongyang People’s Hospital, Jinhua, China
Zhenyan Xu: Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Haige Ye: Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

DOI: https://doi.org/10.3389/fimmu.2024.1348852
Journal volume & issue: Vol. 15

Abstract

Read online

CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords